Sign up to access historical data
Similar companies
| Company | Est. Transaction Value | |
|---|---|---|
 |
Boston ScientificBSX |
-$580,000 |
 |
MedtronicMDT |
-$110,000 |
 |
Edwards LifesciencesEW |
$49,000 |
 |
Intuitive SurgicalISRG |
$16,000 |
 |
MedpaceMEDP |
-$32,000 |
Trades by US Politicians
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Lisa McClain | Jul 16, 2025 | Sell | $1K - $15K |
| Lisa McClain | Jun 17, 2025 | Buy | $1K - $15K |
| Rob Bresnahan | May 15, 2025 | Buy | $1K - $15K |
| Jefferson Shreve | May 12, 2025 | Sell | $15K - $50K |
| Jefferson Shreve | Apr 17, 2025 | Buy | $15K - $50K |
| Rob Bresnahan | Apr 8, 2025 | Sell | $1K - $15K |
| Julie Johnson | Apr 1, 2025 | Sell | $1K - $15K |
| Jefferson Shreve | Mar 13, 2025 | Sell | $15K - $50K |
| Julie Johnson | Mar 3, 2025 | Sell | $1K - $15K |
| Ro Khanna | Oct 14, 2024 | Buy | $1K - $15K |
| Thomas Tuberville Republican | Apr 5, 2024 | Buy | $1K - $15K |
FAQ - Congress Trading
Lisa McClain sold Agilent Technologies shares most recently on July 16, 2025.
Jefferson Shreve has bought the most A stock in the last 2 years, with an estimated value of $33,000.
Jefferson Shreve has sold the most A stock in the last 2 years, with an estimated value of $66,000.
The net value of trades by US politicians for Agilent Technologies in the last 2 years is negative, amounting to -$33,000. This suggests that US politicians do not believe in the success of the company for various reasons.
Over the last 2 years, insider transactions for Agilent Technologies have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering politicians might have insights or reasons not immediately apparent to the public.
Monitoring US politicians' stock trades is valuable because they may have inside information about upcoming policies that could affect stock values, providing investors with valuable clues for making informed decisions.
